Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMI's test catches lung cancer early, study finds:

This article was originally published in Clinica

Executive Summary

IMI International Medical Innovations has revealed that its LungAlert sputum test for lung cancer detected 20 of 23 cancers in a pilot study of the product. Most significantly, the test detected 13 of 15 early stage cancers, which are often still treatable, according to data from the 76-patient study, presented at last month's American Thoracic Society meeting in San Francisco. IMI, of Toronto, Canada, is investigating whether the noninvasive, quantitative test can provide a new screening tool for lung cancer (see Clinica No 946, p 18).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel